Novo Nordisk (NVO) fell -3% and Eli Lilly (LLY) -2% after US President Donald Trump suggested obesity drug prices could fall much lower, though officials clarified that GLP-1 prices have not yet been negotiated.
Join our Mailing list!
Sign up to get all the latest financial news and business updates.
Please fill in the form and we will get in touch with you shortly and help answer any questions you may have about Offshore Supporting services.
